The Food and Drug Administration Sept. 18 approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels, the FDA said. The drug is manufactured by Indianapolis-based Eli Lilly and Co.
Eli Lilly said in a statement that it plans to make Trulicity 0.75 mg and 1.5 mg single-dose pens available for adults in the U.S. later in 2014.
“Type 2 diabetes is a serious chronic condition that causes blood ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.